Smith & Nephew plc
ISIN US83175M2052
|WKN 939163
Overview
Description
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Healthcare Healthcare Equipment General Medical Devices United Kingdom
Financials
Key metrics
| Market capitalisation, EUR | 10,233.14 m |
| EPS, EUR | - |
| P/B ratio | 2.09 |
| P/E ratio | 41.58 |
| Dividend yield | 2.91% |
Income statement (2023)
| Revenue, EUR | 5,132.73 m |
| Net income, EUR | 243.27 m |
| Profit margin | 4.74% |
What ETF is Smith & Nephew plc in?
There is 1 ETF which contains Smith & Nephew plc.
| ETF | Weight | Investment focus | Holdings | TER | Fund size (in m EUR) | Return 1Y | WKN | ISIN |
|---|---|---|---|---|---|---|---|---|
| VanEck Bionic Engineering UCITS ETF A | 3.07% | Equity Health Care Social/Environmental Ageing Population | 25 | 0.55% | 6 | -1.47% | A3DT2R | IE0005TF96I9 |
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.